Successful treatment of erythema nodosum with salazosulfapyridine in a 9-year-old patient with chronic non-bacterial osteomyelitis.

Autor:	Shimomura M; Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center, Sapporo, Japan., Okura Y; Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center, Sapporo, Japan., Takahashi Y; Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center, Sapporo, Japan., Kobayashi I; Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center, Sapporo, Japan.
Jazyk:	angličtina
Zdroj:	Modern rheumatology case reports [Mod Rheumatol Case Rep] 2024 Jul 08; Vol. 8 (2), pp. 394-397.
DOI:	10.1093/mrcr/rxae020
Abstrakt:	We report a 9-year-old Japanese girl with chronic non-bacterial osteomyelitis (CNO) accompanied by recurrent erythema nodosum (EN) which was successfully treated with salazosulfapyridine (SASP). She was referred to our hospital because of recurrent erythema on her lower extremities and persistent knee and ankle arthralgia, which had been present for approximately 1 year. Although naproxen, a nonsteroidal anti-inflammatory drug, was initiated, her symptoms frequently recurred. Magnetic resonance imaging demonstrated multiple distinct high-intensity signals in the talus bones suggestive of multiple bone oedemas. Additionally, a histological examination of erythematous lesions was consistent with the histopathological findings of EN. She was diagnosed as having CNO complicated by EN, and received 250 mg/day of SASP as a second-line treatment, which showed partial response of both skin and bone lesions. Following increase in the dose of SASP to 500 mg/day resulted in complete remission of her skin and bone lesions. In conclusion, our findings suggest that SASP is effective not only for CNO bone lesions but also for EN. SASP could serve as a second-line therapeutic option at least for some cases of CNO complicated by EN refractory to nonsteroidal anti-inflammatory drugs. (© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site–for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu